DOCSLIB.ORG

The Nitrate-Nitrite-Nitric Oxide Pathway

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Nitrate-Nitrite-Nitric Oxide Pathway 1521-0081/72/3/692–766$35.00 https://doi.org/10.1124/pr.120.019240 PHARMACOLOGICAL REVIEWS Pharmacol Rev 72:692–766, July 2020 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: CHRISTOPHER J. GARLAND The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway V. Kapil, R. S. Khambata, D. A. Jones, K. Rathod, C. Primus, G. Massimo, J. M. Fukuto, and A. Ahluwalia William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom (V.K., R.S.K., D.A.J., K.R., C.P., G.M., A.A.) and Department of Chemistry, Sonoma State University, Rohnert Park, California (J.M.F.) Abstract ...................................................................................694 Significance Statement. ..................................................................694 I. Introduction . ..............................................................................694 A. Chemistry of ·NO and Its Metabolism to Nitrite and Nitrate . .........................695 II. Inorganic Nitrite and Nitrate . ............................................................697 A. Historical Uses of Inorganic Nitrite.....................................................697 B. Historical Uses of Inorganic Nitrate ....................................................698 III. Sources and Pharmacokinetics of Nitrate . ................................................698 Downloaded from A. Endogenously Derived Nitrate..........................................................698 B. Exogenous Sources of Nitrate ..........................................................699 1. Dietary Intake ......................................................................699 2. Water Supplies . ..................................................................699 C. Pharmacokinetics of Nitrate ............................................................699 D. Enterosalivary Circulation and Oral Reduction of Nitrate ...............................700 by guest on October 2, 2021 E. Nitrate Reductases. ..................................................................702 1. Prokaryotic Nitrate Reductases .....................................................702 2. Mammalian Nitrate Reductase Activity . ..........................................702 IV. Sources and Pharmacokinetics of Nitrite . ................................................703 A. Endogenously Derived Nitrite from the Enterosalivary Circuit . .........................703 B. Endogenously Derived Nitrite from NOS Activity . .....................................704 C. Exogenous Sources of Nitrite ...........................................................704 D. Systemic Nitrite Absorption ............................................................705 V. Mechanisms of Nitrite Bioactivation. ......................................................706 A. Nonenzymatic Nitrite Reduction. ......................................................706 B. Mammalian Nitrite Reductases. ......................................................706 1. Molybdenum-Containing Oxidase Enzymes ..........................................706 a. Xanthine oxidoreductase. ......................................................706 b. Aldehyde oxidase ................................................................708 c. Sulfite oxidase. ..................................................................709 d. Mitochondrial amidoxime reducing component ...................................709 2. Mitochondrial Respiratory Chain Enzymes ..........................................709 3. Globins .............................................................................709 a. Hemoglobin . ..................................................................709 b. Myoglobin .......................................................................710 c. Neuroglobin . ..................................................................710 d. Cytoglobin.......................................................................710 4. Indoleamine 2,3-Dioxygenase 1......................................................711 Address correspondence to: A. Ahluwalia, Centre for Cardiac Medicines and Device Innovation, William Harvey Research Institute, Charterhouse Square, London EC1M 6BQ, UK. E-mail: [email protected] V.K. and D.A.J. were supported by a Barts Charity Programme grant, C.P. by a Derek Willoughby clinical research training fellowship, and K.R. by a National Institute for Health Academic Clinical Lectureship award. https://doi.org/10.1124/pr.120.019240. 692 Nitrate-Nitrite-Nitric Oxide Pathway 693 5. Nitric Oxide Synthase . ............................................................711 6. Carbonic Anhydrase ................................................................711 VI. Functional Effects of the Noncanonical ·NO Pathway and Clinical Translation . .............712 A. Nitrite, Nitrate, and the CV System ....................................................712 1. Vasodilation ........................................................................712 2. Blood Pressure . ..................................................................714 3. Enterosalivary Generation of Nitrite Regulates Basal BP . .........................719 4. Endothelial Dysfunction ............................................................720 5. Arterial Stiffness . ..................................................................720 6. Cerebral Blood Flow ................................................................721 B. Nitrite and Nitrate in Exercise and Muscle Biology .....................................721 1. Nitrate and Exercise Performance on Moderately Trained Athletes ..................722 a. Mechanisms for enhanced exercise performance after nitrate supplementation . 723 2. Nitrate and Exercise Performance in Patient Populations. .........................724 3. Cardiac Muscle Function and Heart Failure .........................................725 a. ·NO as an inotrope . ............................................................725 b. Cardiac hypertrophy and ·NO....................................................727 c. Positive inotropic and antihypertrophic effects of nitrite and nitrate . .............727 d. Preclinical studies: cardiac dysfunction, nitrite, and nitrate.......................727 e. Clinical translation . ............................................................730 C. Nitrite and Nitrate in Inflammation ....................................................731 1. Thrombosis . ........................................................................735 2. Peripheral Arterial Disease . ......................................................737 3. Atherosclerosis . ..................................................................737 D. Nitrite and Nitrate in the Respiratory System ..........................................738 1. Pulmonary Hypertension............................................................739 2. Chronic Obstructive Pulmonary Disease . ..........................................740 3. Sleep-Disordered Breathing . ......................................................740 4. Toxic Lung Injury. ..................................................................741 E. Nitrite and Nitrate in the GI System . ................................................741 F. Nitrite and Nitrate in Metabolic Diseases...............................................742 G. Nitrite and Nitrate in I/R Injury. ......................................................743 1. Cytoprotection ......................................................................743 2. Potential Mechanisms for Nitrite-Induced Reduction in I/R Injury ...................743 3. Potential Mechanisms for Nitrite-Induced Cytoprotection in I/R Injury . .............744 a. Improved mitochondrial function. ................................................744 b. Antiplatelet effects . ............................................................745 ABBREVIATIONS: ABP, ambulatory blood pressure; ADI, acceptable daily intake; AMI, acute myocardial infarction; AMPK, AMP- activated protein kinase; AO, aldehyde oxidase; ApoE, apolipoprotein E; BNP, brain natriuretic peptide; BP, blood pressure; CABG, coronary artery bypass grafting; CCL2, chemokine (C-C motif) ligand 2; cGMP, cyclic GMP; COPD, chronic obstructive pulmonary disease; C-PTIO, 2- (4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; CV, cardiovascular; CVD, cardiovascular disease; CXCL2, chemokine (C-X-C motif) ligand 2; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; deoxyHb, deoxyhemoglobin; deoxyMb, deoxymyoglobin; dP/dt, rate of change of pressure; DOCA, deoxycorticosterone acetate; EDRF, endothelium-derived relaxing factor; eNOS, endothelial nitric oxide synthase; Fe(II), ferrous; Fe(III), ferric; FMD, flow-mediated dilation; GAG, glycosaminoglycan; GC-1, soluble guanylyl cyclase; GI, gastrointestinal; GTN, glyceryl trinitrate; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICAM-1, intercellular adhesion molecule-1; IDO1, indoleamine 2,3-dioxygenase 1; IL, interleukin; iNO, 1 inhaled·NO; iNOS, inducible nitric oxide synthase; I/R, ischemia/reperfusion; KATP, ATP-sensitive K ; KO, knockout; L-NAME, N(g)--nitro-L- arginine methyl ester; LV, left ventricular; LVEF, left ventricular ejection fraction; MAP, mean arterial
Load more

Recommended publications
  • Nitric Oxide in Health and Disease of the Nervous System H-Y Yun1,2, VL Dawson1,3,4 and TM Dawson1,3
    Molecular Psychiatry (1997) 2, 300–310 1997 Stockton Press All rights reserved 1359–4184/97 $12.00 PROGRESS Nitric oxide in health and disease of the nervous system H-Y Yun1,2, VL Dawson1,3,4 and TM Dawson1,3 Departments of 1Neurology; 3Neuroscience; 4Physiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Nitric oxide (NO) is a widespread and multifunctional biological messenger molecule. It mediates vasodilation of blood vessels, host defence against infectious agents and tumors, and neurotransmission of the central and peripheral nervous systems. In the nervous system, NO is generated by three nitric oxide synthase (NOS) isoforms (neuronal, endothelial and immunologic NOS). Endothelial NOS and neuronal NOS are constitutively expressed and acti- vated by elevated intracellular calcium, whereas immunologic NOS is inducible with new RNA and protein synthesis upon immune stimulation. Neuronal NOS can be transcriptionally induced under conditions such as neuronal development and injury. NO may play a role not only in physiologic neuronal functions such as neurotransmitter release, neural development, regeneration, synaptic plasticity and regulation of gene expression but also in a variety of neurological disorders in which excessive production of NO leads to neural injury. Keywords: nitric oxide synthase; endothelium-derived relaxing factor; neurotransmission; neurotoxic- ity; neurological diseases Nitric oxide is probably the smallest and most versatile NO synthases isoforms and regulation of NO bioactive molecule identified. Convergence of multi- generation disciplinary efforts in the field of immunology, cardio- vascular pharmacology, chemistry, toxicology and neu- NO is formed by the enzymatic conversion of the guan- robiology led to the revolutionary novel concept of NO idino nitrogen of l-arginine by NO synthase (NOS).
    [Show full text]
  • Nitric Oxide Produced by Ultraviolet-Irradiated Keratinocytes Stimulates Melanogenesis
    Nitric oxide produced by ultraviolet-irradiated keratinocytes stimulates melanogenesis. C Roméro-Graillet, … , J P Ortonne, R Ballotti J Clin Invest. 1997;99(4):635-642. https://doi.org/10.1172/JCI119206. Research Article Ultraviolet (UV) radiation is the main physiological stimulus for human skin pigmentation. Within the epidermal-melanin unit, melanocytes synthesize and transfer melanin to the surrounding keratinocytes. Keratinocytes produce paracrine factors that affect melanocyte proliferation, dendricity, and melanin synthesis. In this report, we show that normal human keratinocytes secrete nitric oxide (NO) in response to UVA and UVB radiation, and we demonstrate that the constitutive isoform of keratinocyte NO synthase is involved in this process. Next, we investigate the melanogenic effect of NO produced by keratinocytes in response to UV radiation using melanocyte and keratinocyte cocultures. Conditioned media from UV-exposed keratinocytes stimulate tyrosinase activity of melanocytes. This effect is reversed by NO scavengers, suggesting an important role for NO in UV-induced melanogenesis. Moreover, melanocytes respond to NO-donors by decreased growth, enhanced dendricity, and melanogenesis. The rise in melanogenesis induced by NO-generating compounds is associated with an increased amount of both tyrosinase and tyrosinase-related protein 1. These observations suggest that NO plays an important role in the paracrine mediation of UV-induced melanogenesis. Find the latest version: https://jci.me/119206/pdf Nitric Oxide Produced by Ultraviolet-irradiated Keratinocytes Stimulates Melanogenesis Christine Roméro-Graillet, Edith Aberdam, Monique Clément, Jean-Paul Ortonne, and Robert Ballotti Institut National de la Santé et de la Recherche Médicale U385, Faculté de Médecine, 06107 Nice cedex 02, France Abstract lin-1 (ET-1),1 and GM-CSF by keratinocytes is upregulated after UV light exposure, and these peptides stimulate melanocyte Ultraviolet (UV) radiation is the main physiological stimu- growth (16–19).
    [Show full text]
  • Potential Roles of Nitrate and Nitrite in Nitric Oxide Metabolism in the Eye Ji Won Park1, Barbora Piknova1, Audrey Jenkins2, David Hellinga2, Leonard M
    www.nature.com/scientificreports OPEN Potential roles of nitrate and nitrite in nitric oxide metabolism in the eye Ji Won Park1, Barbora Piknova1, Audrey Jenkins2, David Hellinga2, Leonard M. Parver3 & Alan N. Schechter1* Nitric oxide (NO) signaling has been studied in the eye, including in the pathophysiology of some eye diseases. While NO production by nitric oxide synthase (NOS) enzymes in the eye has been − characterized, the more recently described pathways of NO generation by nitrate ( NO3 ) and nitrite − (NO2 ) ions reduction has received much less attention. To elucidate the potential roles of these pathways, we analyzed nitrate and nitrite levels in components of the eye and lacrimal glands, primarily in porcine samples. Nitrate and nitrite levels were higher in cornea than in other eye parts, while lens contained the least amounts. Lacrimal glands exhibited much higher levels of both ions compared to other organs, such as liver and skeletal muscle, and even to salivary glands which are known to concentrate these ions. Western blotting showed expression of sialin, a known nitrate transporter, in the lacrimal glands and other eye components, and also xanthine oxidoreductase, a nitrate and nitrite reductase, in cornea and sclera. Cornea and sclera homogenates possessed a measurable amount of nitrate reduction activity. These results suggest that nitrate ions are concentrated in the lacrimal glands by sialin and can be secreted into eye components via tears and then reduced to nitrite and NO, thereby being an important source of NO in the eye. Te NO generation pathway from L-arginine by endogenous NOS enzymes under normoxic conditions has been central in identifying the physiological roles of NO in numerous biological processes1.
    [Show full text]
  • Nitric Oxide Signaling in Plants
    plants Editorial Nitric Oxide Signaling in Plants John T. Hancock Department of Applied Sciences, University of the West of England, Bristol BS16 1QY, UK; [email protected]; Tel.: +44-(0)117-328-2475 Received: 3 November 2020; Accepted: 10 November 2020; Published: 12 November 2020 Abstract: Nitric oxide (NO) is an integral part of cell signaling mechanisms in animals and plants. In plants, its enzymatic generation is still controversial. Evidence points to nitrate reductase being important, but the presence of a nitric oxide synthase-like enzyme is still contested. Regardless, NO has been shown to mediate many developmental stages in plants, and to be involved in a range of physiological responses, from stress management to stomatal aperture closure. Downstream from its generation are alterations of the actions of many cell signaling components, with post-translational modifications of proteins often being key. Here, a collection of papers embraces the differing aspects of NO metabolism in plants. Keywords: nitrate reductase; nitration; nitric oxide; reactive oxygen species; stress responses; S-nitrosation; S-nitrosylation; SNO-reductase; thiol modification 1. Introduction Nitric oxide (NO) is now well acknowledged as an instrumental signaling molecule in both plants and animals [1]. First recognized as important as a signal in the control of vascular tone [2], its role in plants came to prominence in the late 1990s [3–5]. The forty years of research into NO in plants has just been highlighted by a review by Kolbert et al. [6]. In plants, NO has been found to be involved in a wide range of developmental stages and physiological responses.
    [Show full text]
  • Nitro-L-Arginine Methyl Ester (L-NAME) Causes Limb Defects in Mouse Fetuses: Protective Effect of Acute Hyperoxia
    0031-3998/03/5401-0069 PEDIATRIC RESEARCH Vol. 54, No. 1, 2003 Copyright © 2003 International Pediatric Research Foundation, Inc. Printed in U.S.A. The Nitric Oxide Synthesis Inhibitor ␻ N -Nitro-L-Arginine Methyl Ester (L-NAME) Causes Limb Defects in Mouse Fetuses: Protective Effect of Acute Hyperoxia GIAN MARIO TIBONI, FRANCA GIAMPIETRO, AND CAMILLO DI GIULIO Sezione di Ostetricia e Ginecologia, Dipartimento di Medicina e Scienze dell’Invecchiamento [G.M.T., F.G.], and Sezione di Fisiologia, Dipartimento di Scienze Biomediche [C.d.G.], Facoltà di Medicina e Chirurgia, Università “G. d’Annunzio”, Chieti, Italy. ABSTRACT In the present study the relationship between exposure to the teratogenesis was investigated. To this aim, a group of L-NAME– ␻ nitric oxide synthesis inhibitor N -nitro-L-arginine methyl ester treated animals (90 mg/kg s.c. on gestation d 14) were exposed (L-NAME) and the induction of limb defects, with respect to to 98 to 100% O2 for 12 h. L-NAME–treated mice breathing stage specificity and dose dependency, was investigated in the room air served as positive controls. In response to hyperoxia, a mouse. ICR (CD-1) mice were dosed s.c with L-NAME at 50 or significant decrement of L-NAME–induced limb defects was 90 mg/kg on gestation d 12, 13, 14, 15, or 16. A group of animals found. This study characterizes for the first time the teratogenic treated with vehicle on gestation d 14 served as control. Uterine capacity of L-NAME in the mouse. Results obtained with hyper- contents were evaluated for teratogenesis on gestation d 18.
    [Show full text]
  • Influence of Functional Variant of Neuronal Nitric Oxide Synthase on Impulsive Behaviors in Humans
    ORIGINAL ARTICLE Influence of Functional Variant of Neuronal Nitric Oxide Synthase on Impulsive Behaviors in Humans Andreas Reif, MD; Christian P. Jacob, MD; Dan Rujescu, MD; Sabine Herterich, PhD; Sebastian Lang, MD; Lise Gutknecht, PhD; Christina G. Baehne, Dipl-Psych; Alexander Strobel, PhD; Christine M. Freitag, MD; Ina Giegling, MD; Marcel Romanos, MD; Annette Hartmann, MD; Michael Rösler, MD; Tobias J. Renner, MD; Andreas J. Fallgatter, MD; Wolfgang Retz, MD; Ann-Christine Ehlis, PhD; Klaus-Peter Lesch, MD Context: Human personality is characterized by sub- Main Outcome Measures: For the association stud- stantial heritability but few functional gene variants have ies, the major outcome criteria were phenotypes rel- been identified. Although rodent data suggest that the evant to impulsivity, namely, the dimensional pheno- neuronal isoform of nitric oxide synthase (NOS-I) modi- type conscientiousness and the categorical phenotypes fies diverse behaviors including aggression, this has not adult ADHD, aggression, and cluster B personality been translated to human studies. disorder. Objectives: To investigate the functionality of an NOS1 Results: A novel functional promoter polymorphism in promoter repeat length variation (NOS1 Ex1f variable NOS1 was associated with traits related to impulsivity, number tandem repeat [VNTR]) and to test whether it including hyperactive and aggressive behaviors. Specifi- is associated with phenotypes relevant to impulsivity. cally, the short repeat variant was more frequent in adult ADHD, cluster B personality disorder, and autoaggres- Design: Molecular biological studies assessed the cel- sive and heteroaggressive behavior. This short variant lular consequences of NOS1 Ex1f VNTR; association came along with decreased transcriptional activity of the studies were conducted to investigate the impact of this genetic variant on impulsivity; imaging genetics was ap- NOS1 exon 1f promoter and alterations in the neuronal plied to determine whether the polymorphism is func- transcriptome including RGS4 and GRIN1.
    [Show full text]
  • Cgmp-Dependent Protein Kinase in Dorsal Root Ganglion: Relationship with Nitric Oxide Synthase and Nociceptive Neurons
    The Journal of Neuroscience, May 15, 1996, W(10):3130-3138 cGMP-Dependent Protein Kinase in Dorsal Root Ganglion: Relationship with Nitric Oxide Synthase and Nociceptive Neurons Yifang Qian,l Daniel S. Chao,’ Daniel R. Santillano,l Trudy L. Cornwell, Angus C. Nairn,4 Paul Greengard,d Thomas M. Lincoln,3 and David S. BredV* 1Deparfment of Physiology and *Program in Biomedical Sciences, University of California San Francisco, San Francisco, California 94 143, 3Deparlmen t of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294, and 4DepaHment of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York IO02 1 Nitric oxide and cGMP influence plasticity of nociceptive pro- and roof plates. Neuronat nitric oxide synthase (nNOS) is co- cessing in spinal cord. However, effecters for cGMP have not expressed with cGKI in sensory neurons during embryonic been identified in sensory pathways. We now demonstrate that development and after peripheral nerve axotomy. The primary cGMP-dependent protein kinase I (cGKI) occurs in the DRGs at target for cGKl in cerebellum, G-substrate, is not present in levels comparable to that in cerebellum, the richest source of developing, mature, or regenerating sensory neurons, indicat- cGKI in the body. Immunohistochemical studies reveal that ing that other proteins serve as effecters for cGKI in sensory cGKI is concentrated in a subpopulation of small- and medium- processing. These data establish sensory neurons as a primary diameter DRG neurons that partially overlap with substance P locus for cGMP actions during development and suggest a role and calcitonin gene-related polypeptide containing cells. Dur- for cGKI in plasticity of nociception.
    [Show full text]
  • Arginase Isoforms Expression of Nitric Oxide Synthase and Populations Of
    Microenvironments in Tuberculous Granulomas Are Delineated by Distinct Populations of Macrophage Subsets and Expression of Nitric Oxide Synthase and This information is current as Arginase Isoforms of September 26, 2021. Joshua T. Mattila, Olabisi O. Ojo, Diane Kepka-Lenhart, Simeone Marino, Jin Hee Kim, Seok Yong Eum, Laura E. Via, Clifton E. Barry III, Edwin Klein, Denise E. Kirschner, Sidney M. Morris, Jr., Philana Ling Lin and JoAnne L. Downloaded from Flynn J Immunol 2013; 191:773-784; Prepublished online 7 June 2013; doi: 10.4049/jimmunol.1300113 http://www.jimmunol.org/content/191/2/773 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/06/07/jimmunol.130011 Material 3.DC1 References This article cites 66 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/191/2/773.full#ref-list-1 by guest on September 26, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • Cellular Distribution and Function of Soluble Guanylyl Cyclase in Rat Kidney and Liver
    ARTICLES J Am Soc Nephrol 12: 2209–2220, 2001 Cellular Distribution and Function of Soluble Guanylyl Cyclase in Rat Kidney and Liver FRANZISKA THEILIG,* MAGDALENA BOSTANJOGLO,* HERMANN PAVENSTADT,¨ † CLEMENS GRUPP,‡ GUDRUN HOLLAND,* ILKA SLOSAREK,* AXEL M. GRESSNER,§ MICHAEL RUSSWURM,࿣ DORIS KOESLING,࿣ and SEBASTIAN BACHMANN* *Department of Anatomy, Charite´, Humboldt University, Berlin, Germany; †Department of Nephrology, University of Freiburg, Freiburg, Germany; ‡Department of Nephrology, University of Go¨ttingen, Go¨ttingen, Germany; §Department of Clinical Chemistry, Rheinisch-Westfa¨lische Technische Hochschule Aachen, Aachen, Germany; and ࿣Department of Pharmacology, Ruhr University, Bochum, Germany. Abstract. Soluble guanylyl cyclase (sGC) catalyzes the biosyn- pendent accumulation of cGMP in cytosolic extracts of tissues thesis of cGMP in response to binding of L-arginine-derived and cells was measured in vitro. Renal glomerular arterioles, nitric oxide (NO). Functionally, the NO-sGC-cGMP signaling including the renin-producing granular cells, mesangium, and pathway in kidney and liver has been associated with regional descending vasa recta, as well as cortical and medullary inter- hemodynamics and the regulation of glomerular parameters. stitial fibroblasts, expressed sGC. Stimulation of isolated mes- The distribution of the ubiquitous sGC isoform ␣1␤1 sGC was angial cells, renal fibroblasts, and hepatic Ito cells with a NO studied with a novel, highly specific antibody against the ␤1 donor resulted in markedly increased cytosolic cGMP levels. subunit. In parallel, the presence of mRNA encoding both This assessment of sGC expression and activity in vascular and subunits was investigated by using in situ hybridization and interstitial cells of kidney and liver may have implications for reverse transcription-PCR assays.
    [Show full text]
  • Arginase As a Potential Biomarker of Disease Progression: a Molecular Imaging Perspective
    International Journal of Molecular Sciences Review Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective Gonçalo S. Clemente 1 , Aren van Waarde 1, Inês F. Antunes 1, Alexander Dömling 2 and Philip H. Elsinga 1,* 1 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; [email protected] (G.S.C.); [email protected] (A.v.W.); [email protected] (I.F.A.) 2 Department of Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +31-50-361-3247 Received: 2 July 2020; Accepted: 23 July 2020; Published: 25 July 2020 Abstract: Arginase is a widely known enzyme of the urea cycle that catalyzes the hydrolysis of L-arginine to L-ornithine and urea. The action of arginase goes beyond the boundaries of hepatic ureogenic function, being widespread through most tissues. Two arginase isoforms coexist, the type I (Arg1) predominantly expressed in the liver and the type II (Arg2) expressed throughout extrahepatic tissues. By producing L-ornithine while competing with nitric oxide synthase (NOS) for the same substrate (L-arginine), arginase can influence the endogenous levels of polyamines, proline, and NO•. Several pathophysiological processes may deregulate arginase/NOS balance, disturbing the homeostasis and functionality of the organism. Upregulated arginase expression is associated with several pathological processes that can range from cardiovascular, immune-mediated, and tumorigenic conditions to neurodegenerative disorders. Thus, arginase is a potential biomarker of disease progression and severity and has recently been the subject of research studies regarding the therapeutic efficacy of arginase inhibitors.
    [Show full text]
  • Using Tyrosinase As a Tri-Modality Reporter Gene to Monitor
    Liu et al. Experimental & Molecular Medicine (2018) 50:54 DOI 10.1038/s12276-018-0080-7 Experimental & Molecular Medicine ARTICLE Open Access Using tyrosinase as a tri-modality reporter gene to monitor transplanted stem cells in acute myocardial infarction Mei Liu1,2,YichunWang1,2, Mengting Li1,2, Hongyan Feng1,2, Qingyao Liu1,2,ChunxiaQin1,2, Yongxue Zhang1,2 and Xiaoli Lan 1,2 Abstract The study aimed to investigate the feasibility of noninvasive monitoring of bone marrow mesenchymal stem cells (MSCs) transduced with the tyrosinase reporter gene for acute myocardial infarction (AMI) with photoacoustic imaging (PAI), magnetic resonance imaging (MRI), and positron emission tomography (PET) in vitro and in vivo. MSCs were transduced with a lentivirus carrying a tyrosinase reporter gene. After transduction, the rate of 18F-5-fluoro-N-(2- [diethylamino]ethyl)picolinamide (18F-5-FPN) uptake was measured. PAI and MRI of stable cell lines expressing tyrosinase (TYR-MSCs) were performed in vitro. An AMI model was induced and verified. TYR-MSCs and MSCs were injected into the margins of the infarcted areas, and PAI, MRI, and PET images were acquired 1, 7, 14, 21, and 28 days after cell injection. Sham-operated models without injection were used as the control group. TYR-MSCs showed noticeably higher uptake of 18F-5-FPN and stronger signals in T1-weighted MRI and PAI than non-transduced MSCs. In vivo studies revealed prominent signals in the injected area of the infarcted myocardium on PAI/MRI/PET images, whereas no signal could be seen in rats injected with non-transduced MSCs or sham-operated rats.
    [Show full text]
  • Rational Design of CYP3A4 Inhibitors: a One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength
    International Journal of Molecular Sciences Article Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength Eric R. Samuels 1 and Irina F. Sevrioukova 2,* 1 Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697-3900, USA; [email protected] 2 Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697-3900, USA * Correspondence: [email protected]; Tel.: +1-949-824-1953 Abstract: Inhibition of the major human drug-metabolizing cytochrome P450 3A4 (CYP3A4) by pharmaceuticals and other xenobiotics could lead to toxicity, drug–drug interactions and other adverse effects, as well as pharmacoenhancement. Despite serious clinical implications, the structural basis and attributes required for the potent inhibition of CYP3A4 remain to be established. We utilized a rational inhibitor design to investigate the structure–activity relationships in the analogues of ritonavir, the most potent CYP3A4 inhibitor in clinical use. This study elucidated the optimal length of the head-group spacer using eleven (series V) analogues with the R1/R2 side-groups as phenyls or R1–phenyl/R2–indole/naphthalene in various stereo configurations. Spectral, functional and structural characterization of the inhibitory complexes showed that a one-atom head-group linker elongation, from pyridyl–ethyl to pyridyl–propyl, was beneficial and markedly improved K , s IC50 and thermostability of CYP3A4. In contrast, a two-atom linker extension led to a multi-fold decrease in the binding and inhibitory strength, possibly due to spatial and/or conformational Citation: Samuels, E.R.; constraints. The lead compound, 3h, was among the best inhibitors designed so far and overall, the Sevrioukova, I.F.
    [Show full text]